These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 27077811)

  • 1. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.
    Clausse V; Goloudina AR; Uyanik B; Kochetkova EY; Richaud S; Fedorova OA; Hammann A; Bardou M; Barlev NA; Garrido C; Demidov ON
    Cell Death Dis; 2016 Apr; 7(4):e2195. PubMed ID: 27077811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer.
    Murakami K; Kita Y; Sakatani T; Hamada A; Mizuno K; Nakamura K; Takada H; Matsumoto K; Sano T; Goto T; Akamatsu S; Saito R; Tsuruyama T; Ogawa O; Kobayashi T
    Cancer Sci; 2021 Sep; 112(9):3669-3681. PubMed ID: 34212455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
    Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
    Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
    Yoda A; Toyoshima K; Watanabe Y; Onishi N; Hazaka Y; Tsukuda Y; Tsukada J; Kondo T; Tanaka Y; Minami Y
    J Biol Chem; 2008 Jul; 283(27):18969-79. PubMed ID: 18482988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.
    Mizuarai S; Yamanaka K; Itadani H; Arai T; Nishibata T; Hirai H; Kotani H
    Mol Cancer; 2009 Jun; 8():34. PubMed ID: 19500427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
    Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
    Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wee1 inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to the anticancer effect of irinotecan.
    Yin Y; Shen Q; Tao R; Chang W; Li R; Xie G; Liu W; Zhang P; Tao K
    Mol Med Rep; 2018 Feb; 17(2):3344-3349. PubMed ID: 29257266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
    Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WIP1, a homeostatic regulator of the DNA damage response, is targeted by HIPK2 for phosphorylation and degradation.
    Choi DW; Na W; Kabir MH; Yi E; Kwon S; Yeom J; Ahn JW; Choi HH; Lee Y; Seo KW; Shin MK; Park SH; Yoo HY; Isono K; Koseki H; Kim ST; Lee C; Kwon YK; Choi CY
    Mol Cell; 2013 Aug; 51(3):374-85. PubMed ID: 23871434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.
    Bridges KA; Hirai H; Buser CA; Brooks C; Liu H; Buchholz TA; Molkentine JM; Mason KA; Meyn RE
    Clin Cancer Res; 2011 Sep; 17(17):5638-48. PubMed ID: 21799033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
    Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN
    Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour suppressive effects of WEE1 gene silencing in breast cancer cells.
    Ghiasi N; Habibagahi M; Rosli R; Ghaderi A; Yusoff K; Hosseini A; Abdullah S; Jaberipour M
    Asian Pac J Cancer Prev; 2014 Jan; 14(11):6605-11. PubMed ID: 24377575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
    Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
    Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors.
    Li Y; Saini P; Sriraman A; Dobbelstein M
    Oncotarget; 2015 Oct; 6(32):32339-52. PubMed ID: 26431163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wee1 kinase as a target for cancer therapy.
    Do K; Doroshow JH; Kummar S
    Cell Cycle; 2013 Oct; 12(19):3159-64. PubMed ID: 24013427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
    Hirai H; Arai T; Okada M; Nishibata T; Kobayashi M; Sakai N; Imagaki K; Ohtani J; Sakai T; Yoshizumi T; Mizuarai S; Iwasawa Y; Kotani H
    Cancer Biol Ther; 2010 Apr; 9(7):514-22. PubMed ID: 20107315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin.
    Shi Y; Felley-Bosco E; Marti TM; Orlowski K; Pruschy M; Stahel RA
    BMC Cancer; 2012 Dec; 12():571. PubMed ID: 23211021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.
    Spinnler C; Hedström E; Li H; de Lange J; Nikulenkov F; Teunisse AF; Verlaan-de Vries M; Grinkevich V; Jochemsen AG; Selivanova G
    Cell Death Differ; 2011 Nov; 18(11):1736-45. PubMed ID: 21546907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
    Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
    Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.
    Osman AA; Monroe MM; Ortega Alves MV; Patel AA; Katsonis P; Fitzgerald AL; Neskey DM; Frederick MJ; Woo SH; Caulin C; Hsu TK; McDonald TO; Kimmel M; Meyn RE; Lichtarge O; Myers JN
    Mol Cancer Ther; 2015 Feb; 14(2):608-19. PubMed ID: 25504633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.